|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-6.33/-6.47
|
企业价值
2.02B
|
资产负债 |
每股账面净值
14.29
|
现金流量 |
现金流量率
--
|
损益表 |
收益
26.82M
|
每股收益
0.42
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/04 23:05 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval. |